Semler Scientific

Semler Scientific, Inc. engages in the provision of technology and software solutions to improve the clinical effectiveness of healthcare providers. Its multi-test service platform, WellChec, comprehensively evaluate its customers patients for chronic disease, including heart attacks and strokes, using its QuantaFlo product as well as other tests. The company was founded by Herbert J. Semler and Shirley L. Semler on August 9, 2007 and is headquartered in Santa Clara, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Semler Scientific posts record revenue and profit growth in Q4

Semler Scientific delivered robust financial performance in Q4 2022, marked by record revenue, profit growth, and a strong cash position.
The company's strengths lie in its revenue diversification, profitability improvement, and strategic leadership transition.
Challenges include managing operating expenses, sustaining revenue growth across segments, and ensuring a smooth CEO transition.
Opportunities for Semler include expansion, innovation in healthcare technologies, and leveraging market demand for its services for future growth.

Semler Scientific achieves record Q1 earnings amidst strategic growth

Semler Scientific delivered robust financial performance in Q1 2023, marked by record revenue and pre-tax net income, underpinned by strong liquidity.
The company's strategic focus on governance, product innovation, and confidence in product benefits positions it well to navigate challenges and seize growth opportunities.
Despite cost management challenges and regulatory uncertainties, Semler's resilience, financial strength, and commitment to innovation bode well for future success.

Semler Scientific reports record revenue and profit growth in Q2

Semler Scientific's Q2 2023 performance showcased robust revenue growth, driven by successful QuantaFlo sales, and a significant increase in pre-tax net income.
The company's strategic initiatives, including leadership changes, product introductions, and operational streamlining, demonstrate a focus on sustainable growth and innovation.
While facing challenges such as cost management and workforce reduction, Semler Scientific is well-positioned to leverage opportunities in market expansion, technology advancements, and clinical benefits delivery.

Semler Scientific excels in Q3 with strong revenue growth

Semler Scientific's Q3 2023 earnings call highlighted robust financial performance, operational efficiency, and growth opportunities. The company's focus on innovation and market expansion positions it well for future success.

Semler Scientific reports solid Q4 earnings, eyes growth in cardiovascular diagnosis

Semler Scientific's Q4 2023 earnings call showcased positive financial performance, strategic growth initiatives, and a commitment to innovation in cardiovascular disease diagnosis.
Despite challenges such as operating expenses and fixed fee revenue decline, the company's adaptability and focus on clinical benefits position it well for future opportunities.
Analyst inquiries and executive responses highlighted a strong emphasis on efficiency improvements, market adaptability, and regulatory clearances for continued growth.

Semler Scientific reports earnings growth, eyes new product clearance

Semler Scientific's Q1 2024 performance showed growth in earnings and effective cost management.
While facing revenue challenges, the company is strategically positioned to capitalize on growth opportunities.
With a focus on innovation and market expansion, Semler aims to drive future revenue growth.
The company's strong financial position and strategic initiatives position it well for future success.

Semler Scientific adopts bitcoin treasury, reports stable Q2 performance

Semler Scientific's Q2 2024 performance reflects a strategic shift towards bitcoin as a treasury asset and a focus on core business operations.
While facing revenue challenges and cost management needs, the company's financial strength and flexibility position it well for future growth.
Opportunities lie in leveraging debt securities for expansion and capitalizing on the potential of bitcoin as a long-term investment.

Semler Scientific reports robust Q3 earnings, diversifies into Bitcoin

Semler Scientific's Q3 2024 performance reflects resilience in income generation and prudent cost control measures.
The company's strategic focus on Bitcoin acquisitions and product innovation positions it for potential growth and market leadership.
While facing revenue challenges and financial risks, Semler's exploration of financing options and regulatory compliance efforts signal a proactive stance.
Opportunities lie in leveraging operational strength for expansion, diversifying investment strategies, and capitalizing on early disease diagnosis capabilities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Semler Scientific, Inc. engages in the provision of technology and software solutions to improve the clinical effectiveness of healthcare providers. Its multi-test service platform, WellChec, comprehensively evaluates its customers’ patients for chronic disease, including heart attacks and strokes, using its QuantaFlo product as well as other tests. The company was founded by Herbert J. Semler, Guinasso Cindy and Shirley L. Semler on August 9, 2007 and is headquartered in Santa Clara, CA.

SANTA CLARA, Calif. , Nov. 18, 2024 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a pioneer in developing and marketing technology products and services to healthcare providers to combat chronic diseases, today announced updates regarding its bitcoin activity and holdings, capital markets activity, and BTC yield, a key performance indicator that it recently adopted.

Semler Scientific® Announces BTC and ATM Activity Raised $21.5 million; Purchased Additional 215 BTC; Now Holds 1,273 BTC with BTC Yield of 37.3%

Semler has delivered 17% returns since we last wrote about it, but we are now looking to revise our stance. SMLR's Q3 earnings which came out yesterday was impressive on the headline front, but revenue attrition persists and will likely worsen in Q4. The onus now will shift to cash conversion, which SMLR continues to facilitate, but the pronounced degree of OPEX contractions looks to be fading.

Semler Scientific: Topline Challenges Persist, While New Treasury Strategy Prompts A Shift

The medical device company has made a peculiar bet on a popular cryptocurrency.

Why Shares of Semler Scientific Stock Jumped 24.5% Last Month

Semler Scientific, Inc. (NASDAQ:SMLR ) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Company Participants Doug Murphy-Chutorian - Chief Executive Officer Eric Semler - Chairman Jennifer Oliva Herrington - Chief Operating Officer Renae Cormier - Chief Financial Officer Conference Call Participants Operator Good afternoon, everyone, and welcome to the Semler Scientific Third Quarter 2024 Financial Results Conference Call. All participants will be in a listen only mode.

Semler Scientific, Inc. (SMLR) Q3 2024 Earnings Call Transcript

SANTA CLARA, Calif. , Nov. 4, 2024 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a pioneer in developing and marketing technology products and services to healthcare providers to combat chronic diseases, today reported financial results for the third quarter ended September 30, 2024.

Semler Scientific® Reports Third Quarter 2024 Financial Results and Additional Bitcoin Purchases

SANTA CLARA, Calif. , Oct. 21, 2024 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a pioneer in developing and marketing technology products and services to healthcare providers to combat chronic diseases, today announced that it will report financial results for the third quarter and nine months ended September 30, 2024, as well as provide an update on its Bitcoin holdings after the close of U.S. financial markets on Monday, November 4, 2024.

Semler Scientific to Report Third Quarter and First Nine Months of 2024 Financial Results, Provide an Update on Bitcoin Holdings and Host Conference Call on November 4, 2024

PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law LLC announces that it is investigating Semler Scientific, Inc. (“Semler”) (NASDAQ: SMLR) on behalf of the company's shareholders. Since February 2024, shares of Semler's stock have declined in value from a trading price of over $51.00 per share to a current trading price of less than $26.00 per share, a decline of nearly 50% in value. The investigation seeks to determine whether Semler and/or the company's officers and directors violated the securities.

Kaskela Law LLC Announces Shareholder Investigation of Semler Scientific, Inc. (NASDAQ: SMLR) and Encourages Investors to Contact the Firm

SANTA CLARA, Calif. , Aug. 26, 2024 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a pioneer in developing and marketing technology products and services to healthcare providers to combat chronic diseases, today announced that it has purchased an additional 83 bitcoins for $5.0 million in cash, inclusive of fees and expenses.

Semler Scientific Announces Additional Bitcoin Purchases

Semler Scientific, Inc. (NASDAQ:SMLR ) Q2 2024 Earnings Conference Call August 5, 2024 4:30 PM ET Company Participants Doug Murphy-Chutorian - Chief Executive Officer Eric Semler - Chairman Jennifer Oliva Herrington - Chief Operating Officer Renae Cormier - Chief Financial Officer Conference Call Participants Operator Good afternoon, and welcome to the Semler Scientific 2024 Second Quarter Financial Results Conference Call. All participants will be in listen-only mode.

Semler Scientific, Inc. (SMLR) Q2 2024 Earnings Call Transcript

SANTA CLARA, Calif. , Aug. 5, 2024 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a pioneer in developing and marketing technology products and services to healthcare providers to combat chronic diseases, today reported financial results for the second quarter ended June 30, 2024.

Semler Scientific® Reports Second Quarter 2024 Financial Results and Additional Bitcoin Purchases

Semler Scientific acquired 828 BTC for $57 million, spending 90% of their cash reserves on Bitcoin purchases. Market has responded positively to the Bitcoin treasury strategy. SMLR's quant metrics are strong, and the QuantaFlo product has a moat.

Semler Scientific's Bitcoin: The Next MicroStrategy?

Semler Scientific has launched a Bitcoin treasury strategy, purchasing $57 billion for its balance sheet this year. The move marks a major pivot compared to the company's medical technology business. The stock price direction is now tied to the direction of Bitcoin, but core operating trends should keep shares volatile.

Semler Scientific: Big Bet On Bitcoin Doesn't Change Big Picture

SANTA CLARA, Calif. , July 22, 2024 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a pioneer in developing and marketing technology products and services to healthcare providers to combat chronic diseases, today announced that it will report financial results for the second quarter and six months ended June 30, 2024, after the close of U.S. financial markets on Monday, August 5, 2024.

Semler Scientific to Report Second Quarter and First Half of 2024 Financial Results and Host Conference Call on August 5, 2024

SANTA CLARA, Calif. , June 6, 2024 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a pioneer in developing and marketing technology products and services to healthcare providers to combat chronic diseases, today announced that it has purchased an additional 247 bitcoins for an aggregate $17 million in cash, inclusive of fees and expenses.

Semler Scientific® Announces Additional Bitcoin Purchases

Semler Scientific has committed to a Bitcoin-based treasury plan, starting with a $40 million crypto investment. The stock surged 43% after this announcement.

Semler Scientific's Bitcoin Bet Sends Stock Soaring 43%

SANTA CLARA, Calif. , May 28, 2024 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a pioneer in developing and marketing technology products and services to healthcare providers to combat chronic diseases, announced today that its board of directors has adopted bitcoin as its primary treasury reserve asset.

Semler Scientific® Announces Bitcoin Treasury Strategy

Semler Scientific's primary product, QuantaFlo, is a fast and easy-to-use device for diagnosing peripheral arterial disease. Its stock has dropped nearly 50% in value, presenting a potential opportunity for investors. Despite losin

Semler Scientific: Great Product Can Still Thrive Post Medicare Advantage

Semler Scientific, Inc. (NASDAQ:SMLR ) Q1 2024 Results Conference Call May 7, 2024 4:30 PM ET Company Participants Doug Murphy-Chutorian - Chief Executive Officer Renae Cormier - Chief Financial Officer Jennifer Oliva Herrington - Chief Operating Officer Conference Call Participants Aaron Wukmir - Lake Street Capital Operator Good afternoon, and welcome to the Semler Scientific 2024 First Quarter Financial Results Conference Call. [Operator Instructions].

Semler Scientific, Inc. (SMLR) Q1 2024 Earnings Call Transcript

2024 Q1 highlights compared to the corresponding period of 2023: First quarter revenues were $15.9 million, a decrease of 13% First quarter net income was $6.1 million, an increase of 22% Cash, cash equivalents and restricted cash balance increased to $62.9 million SANTA CLARA, Calif. , May 7, 2024 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a company that develops, manufactures and markets innovative medical products and services that assist in evaluating and treating chronic diseases, today reported financial results for the first quarter ended March 31, 2024.

Semler Scientific® Reports First Quarter 2024 Financial Results

SMLR has a competitive product (QuantaFlo) in the cardiovascular diagnostic space, and is currently awaiting a 510(k) clearance for expanded use, which could potentially arrive in H2-24. Semler's cash generating prowess has picked up over time, and currently 73% of its asset base consists of cash alone. P/E Valuations are cheap, and buyback momentum is likely to step up.

Semler Scientific: Not Perfect But Worth Considering

SANTA CLARA, Calif. , April 23, 2024 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a company that develops, manufactures and markets innovative medical products and services that assist in evaluating and treating chronic diseases, today announced that it will report financial results for the first quarter ended March 31, 2024, after the close of U.S. financial markets on Tuesday, May 7, 2024.

Semler Scientific to Report First Quarter Financial Results and Host Conference Call on May 7, 2024

AMN Healthcare Services

Bristol-Myers

CVS Health

Patterson Companies

Royalty Pharma

Voyager Therapeutics

With the market trading near all-time highs, undervalued healthcare stocks offer a compelling opportunity. Fundamentally, the sector could benefit from a rotation in the innovation ecosystem.

The Healthcare Bargain Blitz: 7 Undervalued Stocks to Inject into Your Portfolio

Semler Scientific, Inc. (NASDAQ:SMLR ) Q4 2023 Earnings Conference Call March 5, 2024 4:30 PM ET Company Participants Doug Murphy-Chutorian - Chief Executive Officer Renae Cormier - Chief Financial Officer Jennifer Oliva Herrington - Chief Operating Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Operator Good afternoon, and welcome to the Semler Scientific 2023 Fourth Quarter Financial Results Conference Call. All participants will be in a listen-only mode [Operator Instructions].

Semler Scientific, Inc. (SMLR) Q4 2023 Earnings Call Transcript

2023 Q4 and full year highlights compared to the corresponding period of 2022: Fourth quarter revenues were $15.1 million, an increase of 9% Fourth quarter net income was $4.2 million, an increase of 31% Full year revenues were $68.2 million, an increase of 20% Full year net income was $20.6 million, an increase of 44% Cash balance increased to $57.3 million SANTA CLARA, Calif. , March 5, 2024 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a company that develops, manufactures and markets innovative medical products and services that assist in evaluating and treating chronic diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023.

Semler Scientific Reports Fourth Quarter and Full Year 2023 Financial Results

SANTA CLARA, Calif. , Feb. 21, 2024 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a company that develops, manufactures and markets innovative medical products and services that assist in evaluating and treating chronic diseases, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2023, after the close of U.S. financial markets on Tuesday, March 5, 2024.

News for Semler Scientific Stock (SMLR)